Breakthrough therapy designation for GSK5764227 based on preliminary data from the ongoing ARTEMIS-001 Phase I trial, which showed the novel therapy’s promise treating patients with relapsed or refractory extensive-stage small-cell lung cancer.
FDA Grants Breakthrough Therapy Designation to GSK’s GSK5764227 for Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer